The Neurotechnology Industry 2011 Report: Exhibits, Tables, and Charts
1-1: Number of Individuals Afflicted by Indication, US and Worldwide, Top 15 Indications
1-2: Global Pharmaceutical Sales by Indication, 2010
1-3: Neurotechnology Industry Taxonomy
1-4: Proportion of Patient Population Segmented by Neurotech Market Opportunity
1-5: NASDAQ NeuroInsights Neurotech Index Performance vs. S&P500, NASQAQ Composite, and NASDAQ Biotechnology Index
2-1: Projected Percentage Increase in Global Populations aged 65 and over, 1994-2020
2-2: Neuropharmaceutical Patent Expirations and Generic Competition, 2003-2015
2-3: Neurotechnology Patent Approvals, US, 1985-2007
2-4: Neuropharmaceutical Patent Approvals, US, 1985-2007
2-5: Neurodevice Patent Approvals, US, 1985-2007
2-6: Neurodiagnostic Patent Approvals, US, 1985-2007
2-7: Selected US Foundations with a Significant focus on Brain Research and Education
2-8: Most Generous Philanthropists for Medical and Brain Research
2-9: Global Stem Cell Policy Map
3-1: Neuropharmaceutical Revenues by Indication (2010)
3-2: FDA Pharmaceutical Approval Process
3-3: Big Pharma neuropharmaceutical revenues
3-4: Neuropharmaceutical Partnering and Licensing Deals 2004-Q1 2011
3-5: Clinical Trials for Alzheimer’s disease (company, compound, phase, mechanism)
3-6: Clinical Trials for AAMI and MCI (company, compound, phase, mechanism)
3-7: Clinical Trials for Epilepsy (company, compound, phase, mechanism)
3-8: Clinical Trials for Huntington’s disease (company, compound, phase, mechanism)
3-9: Clinical Trials for Migraine (company, compound, phase, mechanism)
3-10: Clinical Trials for Multiple sclerosis (company, compound, phase, mechanism)
3-11: Clinical Trials for Parkinson’s disease (company, compound, phase, mechanism)
3-12: Clinical Trials for sleep disorders (company, compound, phase, mechanism)
3-13: Clinical Trials for stroke Treatment (company, compound, phase, mechanism)
3-14: Clinical Trials for traumatic brian injury(company, compound, phase, mechanism)
3-15: Number of People with Addiction and Impulse Control Disorders (WW and US)
3-16: Clinical Trials for addition and substance abuse (company, compound, phase, mechanism)
3-17: Clinical Trials for anxiety disorders (company, compound, phase, mechanism)
3-18: Clinical Trials for ADHD (company, compound, phase, mechanism)
3-19: Clinical Trials for Depressive disorders (company, compound, phase, mechanism)
3-20: Clinical Trials for Obesity Treatment (company, compound, phase, mechanism)
3-21: Clinical Trials for Schizophrenia and psychosis (company, compound, phase, mechanism)
3-22: Clinical Trials for Retinal disorders (company, compound, phase, mechanism)
3-23: Clinical Trials for Nociceptive Pain (company, compound, phase, mechanism)
3-23: Clinical Trials for Neuropathic Pain (company, compound, phase, mechanism)
4-1: FDA Classification and Approval Process for Medical Devices
4-2: Neurodevice Acquisition and Investment Activity: Medtronic, Boston Scientific, J&J
4-3: Neurodevice Markets and Revenues (Neuroprosthetic, Neuromodulation, Neurosurgical, Neurofeedback)
4-4: Neuromodulation Device Clinical Trials
5-1: Neurodiagnostics Markets and Annual Growth (Neuroimaging, In Vitro Diagnostics, Neuroinformatics)
5-2: FDA Approval and Insurance Reimbursement of Diagnostics
5-3: Neuroimaging Technology (CT, MRI, fMRI, PET, SPECT, EEG, MEG)
5-6: Alzheimer’s Disease Neuroimaging Initiative
5-7: Neuroinformatics Data Storage
5-8: Paul Allen Brain Atlas Project and IBM Blue Brain Project
6-1: Total US Venture Capital Investment, 1999-2010
6-2: US Life Science Venture Capital Investment, 1999-2010
6-3: US Neurotechnology Venture Capital Investment, 1999-2010
6-4: Neurotech as Percent of Life Science Venture Investment, 1999-2010
6-5: Top Five Neurotechnology Venture Capital Financings, 2001-2010
6-6: Top 12 Neurotech Venture Capital Firms with Investments
7-1: Neurotechnology Initial Public Offerings US, 2004-Q1 2011
7-2: Selected Neurotech M&A Activity, 2004-Q1 2011
7-3: Neurotech Index Companies 2011
7-4: Neurotech Index Company Fundamentals
7-5: Index Company Performance
8-1 Leading Neurotechnology Research Centers
8-2 Neurotech Research Centers and Affiliated Institutes, Funding, Recent Significant Investments, Reputation, Translation of Discoveries to Industry
8-3: UCSF
8-4: UCLA
8-5: Harvard University
8-6: Stanford University
8-7: MIT
8-8: Columbia University
8-9: Washington University
8-10: University College London
8-11: Karolinska Institute
8-12: RIKEN Brain Science Institute
9-1 NeuroInsights’ Leading Neurotech Nexus Ratings
9-2 Conclusions and Policy Recommendations
10-1 Neuropharmaceutical Companies Private Profiles (status, funding, location, investment, descriptions, investors)
10-2 Neuropharmaceutical Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
10-3 Neurodevice Companies Private Profiles (status, funding, location, investment, descriptions, investors)
10-4 Neurodevice Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
10-5 Neurodiagnostic Companies Private Profiles (status, funding, location, investment, descriptions, investors)
10-6 Neurodiagnostic Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
|
|